IGC Pharma, Inc. (IGC) is a publicly traded Industrials sector company. As of May 20, 2026, IGC trades at $0.30 with a market cap of $28.26M and a P/E ratio of -3.08. IGC moved -1.43% today. Year to date, IGC is -3.09%; over the trailing twelve months it is -9.00%. Its 52-week range spans $0.24 to $0.50. Analyst consensus is buy with an average price target of $5.25. Rallies surfaces IGC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial and Posts Q1 Results: IGC Pharma advanced its Phase 2 CALMA trial for IGC-AD1 to roughly 80% enrollment across 146 targeted patients, while expanding its clinical site network. The company recorded a Q1 net loss of $2.4 million on $317 thousand revenue and increased R&D spending to $1.3 million, driven by trial progression.
| Metric | Value |
|---|---|
| Price | $0.30 |
| Market Cap | $28.26M |
| P/E Ratio | -3.08 |
| EPS | $-0.09 |
| Dividend Yield | 0.00% |
| 52-Week High | $0.50 |
| 52-Week Low | $0.24 |
| Volume | 642.81K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.27M |
| Net Income | $-7.12M |
| Gross Margin | 48.70% |
1 analysts cover IGC: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.25.